Full-Time

Senior Manager, ACAS/Commercial Benefits Testing

Deadline 8/31/26
CVS Health

CVS Health

10,001+ employees

Healthcare, insurance, PBM, and retail pharmacy

Compensation Overview

$82.9k - $182.5k/yr

+ Bonus + Commission + Short-term incentive + Equity award

Company Historically Provides H1B Sponsorship

Connecticut, USA

Remote

Bachelor's

Category
Engineering Management (1)
Required Skills
Software Testing
Quality Assurance (QA)

Get referred to CVS Health

See people who can refer or advise you

Requirements
  • At least 7 years of experience in healthcare technology or operations, with deep exposure to claims adjudication and benefits configuration.
  • At least 5 years of experience in quality engineering, testing leadership, or quality assurance management roles.
  • Strong experience with claims adjudication systems and benefits testing, such as ACAS or similar platforms.
  • Proven ability to design risk-based and scenario-driven testing strategies.
  • Experience leading teams and influencing quality outcomes across cross-functional stakeholders.
  • Strong analytical, problem-solving, and decision-making skills.
  • A bachelor's degree or equivalent relevant work experience.
Responsibilities
  • Define and drive the quality engineering strategy for ACAS benefits testing in alignment with enterprise Testing Center of Excellence standards.
  • Champion shift-left quality practices, including early validation of requirements, benefit configurations, and adjudication logic.
  • Establish engineering-led approaches to defect prevention, testability, and quality gates.
  • Lead the adoption and expansion of automation-first testing for benefits and claims adjudication scenarios.
  • Partner with automation architects and engineers to design scalable test frameworks, reusable assets, and data strategies.
  • Define risk-based testing models focused on high-impact benefit configurations and claim scenarios.
  • Guide teams in assessing claim exposure, financial risk, and member or client impact associated with defects.
  • Analyze defect trends to identify systemic issues and inform upstream process or design improvements.
  • Establish and monitor quality key performance indicators, including defect leakage, automation coverage, test effectiveness, and rework reduction.
  • Drive continuous improvement initiatives to improve testing efficiency, consistency, and outcomes.
  • Contribute to enterprise testing standards, best practices, and governance frameworks within the Testing Center of Excellence.
  • Serve as a senior quality engineering partner to engineering, configuration, business, and audit teams.
  • Influence design and configuration decisions by providing early quality and risk insights.
  • Communicate quality risks, trends, and recommendations clearly to senior stakeholders.
Desired Qualifications
  • Experience in commercial health benefits and claims processing.
  • Familiarity with ACAS, PERS, or comparable adjudication platforms.
  • Strong executive-level communication skills and the ability to translate complex quality risks into business impact.

CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Woonsocket, Rhode Island

Founded

1963

Get referred to CVS Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CVS raised 2026 adjusted EPS guidance to $7.90-$8.10 on August 5, 2026.
  • CVS and Eli Lilly launch Zepbound and Foundayo pricing in-app by early Q4 2026.
  • CVS opened pharmacy-focused Houston stores and plans nearly 20 nationwide openings.

What critics are saying

  • Reuters said Caremark expects weaker client retention after August 5, 2026 results.
  • Louisiana settled three PBM lawsuits with CVS for $45 million on February 20, 2026.
  • Tennessee's FAIR Rx Act threatens 137 CVS pharmacies and MinuteClinics, risking forced divestiture.

What makes CVS Health unique

  • CVS integrates Aetna, Caremark, and 9,000 pharmacies across U.S. scale.
  • August 5, 2026 results showed all three segments beat revenue expectations.
  • Teresa Heitsenrether joins the board November 18, 2026, signaling data-driven healthcare execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Company Equity

Wellness Program

Professional Development Budget

Paid Vacation

Paid Holidays

Company News

Yahoo Finance
Aug 19th, 2026
CVS Health appoints JPMorgan data executive to board as focus shifts to digital healthcare

CVS Health has appointed Teresa Heitsenrether, a senior executive from JPMorgan Chase with extensive data and analytics experience, to its board of directors. The move follows the resignation of board member Larry M. Robbins. The appointment signals CVS Health's focus on technology and data-driven healthcare at the governance level. The company, valued at approximately $120bn, operates an integrated healthcare model spanning insurance, pharmacy benefits, and retail services. Heitsenrether's data expertise aligns with CVS Health's strategy to leverage digital capabilities and operational efficiency across its businesses, including Aetna and Caremark. The company faces challenges including high debt levels and reimbursement pressures in a competitive market alongside UnitedHealth Group and Cigna.

Yahoo Finance
Aug 14th, 2026
CVS Health beats Q2 revenue and profit estimates but faces questions on sustainability

CVS Health reported second quarter revenue of $106.1 billion, beating analyst estimates of $99.41 billion by 6.7%. Adjusted earnings per share came in at $2.58, surpassing expectations of $1.85 by 39.4%. Management attributed strong performance to specialty pharmacy and Medicare Advantage, with CEO David Joyner noting improvements from actions taken in Aetna and Caremark. The company raised its full-year adjusted EPS guidance to $8 at the midpoint. However, analysts raised concerns about sustainability. Management acknowledged ongoing challenges in the 340B program and normalisation of script share gains from Rite Aid. To offset these headwinds, executives pointed to biosimilars and investments in service technology. The company has committed $20 billion over a decade to AI and technology investments, with operational savings already being realised.

Fox Business
Aug 13th, 2026
Nine major PBMs to display TrumpRx prescription drug prices from 2027

Nine pharmacy benefit managers will integrate TrumpRx prescription drug pricing into their benefit tools, effective 1 January 2027. The Pharmaceutical Care Management Association and participating PBMs—including CVS Health, Express Scripts, Humana, and OptumRx—will display cash prices from TrumpRx alongside plan coverage costs. The agreement covers commercial, Medicare, and Medicaid plans. Patients will see TrumpRx prices for all listed drugs, whether through presidential deals or standard pricing. CMS Administrator Dr Mehmet Oz said the commitment will help patients compare prices and find better deals. PCMA CEO David Marin stated the transparency will allow consumers to make better-informed choices about prescription drug costs. Some PBMs will use Real Time Benefit Tools to display pricing comparisons, whilst others may employ different methods.

Yahoo Finance
Aug 11th, 2026
AbbVie acquires Apogee Therapeutics for $10.9B amid pipeline expansion

AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics in June 2026, aiming to strengthen its drug pipeline. The biopharmaceutical company reported FY 2025 revenue of nearly $61.2 billion, up roughly 8.6% year-on-year. Net income reached close to $4.2 billion, reflecting a net margin of approximately 6.9%, down from 7.6% the previous year. Free cash flow for the period was nearly $17.8 billion. CVS Health reported FY 2025 revenue of approximately $402.1 billion, representing growth of nearly 7.8%. The integrated healthcare provider serves around 37 million medical members and manages 1.9 billion prescriptions annually through its Health Services segment. Net income was close to $1.8 billion, yielding a net margin of roughly 0.4%, down from 1.2% in FY 2024.

Yahoo Finance
Aug 5th, 2026
CVS Health Q2 earnings beat expectations, partners with Eli Lilly on weight loss drugs

CVS Health reported second-quarter net income of $2.98 billion, or $2.31 per share, significantly beating analyst expectations of $1.85 per share. Revenue rose 7% to $106.10 billion, surpassing the forecast of $100.11 billion. The company raised its full-year adjusted earnings guidance to between $7.90 and $8.10 per share, up from $7.30 to $7.50 per share. Revenue guidance increased to at least $414 billion from $405 billion. CVS announced a partnership with Eli Lilly, with the CVS Health app to display pricing for Lilly's weight loss drugs Zepbound and Foundayo starting in early fourth quarter 2026. The company also reduced MinuteClinic virtual weight loss consultations to $29, eliminating membership fees.